California Launches $11 Insulin to Combat High Prices for Diabetics

Californians with diabetes will soon have access to significantly lower-priced insulin as part of a new initiative announced by Governor Gavin Newsom. Starting on January 1, 2024, the state plans to offer long-acting insulin pens at just $11 each, or $55 for a five-pack. This move aims to address the rising costs associated with diabetes management and ensure that no resident is forced to ration their medication.

The insulin pens will serve as a substitute for glargine, the generic version of Lantus, which is typically priced over $92 at pharmacies, according to data from Newsom’s office. The governor emphasized the urgency of this issue, stating, “California didn’t wait for the pharmaceutical industry to do the right thing — we took matters into our own hands. No Californian should ever have to ration insulin or go into debt to stay alive.”

Approximately 3.5 million residents in California are living with diabetes, as reported by the American Diabetes Association. The financial burden of insulin has garnered attention from lawmakers at both state and federal levels. Recent price caps introduced by the Biden administration in 2023 and increased public scrutiny have contributed to a national decline in insulin prices.

CalRx Initiative Aims to Improve Medication Access

The launch of the state-branded insulin is part of California’s CalRx initiative, which seeks to reduce prescription drug costs for its residents. This announcement marks a significant step toward fulfilling Newsom’s earlier promise to address insulin pricing, a commitment made three years ago. The state had initially allocated $50 million to partner with Civica Rx, a nonprofit drug manufacturer based in Utah, and another $50 million to establish a manufacturing facility in California, although updates on this facility are currently lacking.

Elizabeth Landsberg, director of the state healthcare access department overseeing CalRx, stated that the program is dedicated to “transparent pricing, eliminating hidden costs, and ensuring equitable medication access for uninsured, underinsured, and vulnerable residents.” This initiative aims to provide relief to those who struggle with the high costs of necessary medications.

In conjunction with this program, Newsom recently signed a law that caps out-of-pocket insurance costs for insulin at $35. This legislation, combined with the introduction of state-branded insulin, represents a concerted effort to alleviate the financial strain on individuals managing diabetes in California.

As the state prepares for the rollout of this program, it remains to be seen how this initiative will impact the daily lives of the millions of Californians who rely on insulin to manage their health. The hope is that these changes will not only make insulin more affordable but also set a precedent for other states facing similar challenges in healthcare access and affordability.